Royal Bank of Canada’s Neurogene NGNE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $2K | Sell |
112
-318
| -74% | -$6.16K | ﹤0.01% | 6729 |
|
|
2025
Q4 | $9K | Buy |
430
+19
| +5% | +$473 | ﹤0.01% | 6476 |
|
|
2025
Q3 | $7K | Sell |
411
-709
| -63% | -$14.2K | ﹤0.01% | 6604 |
|
|
2025
Q2 | $16K | Buy |
1,120
+606
| +118% | +$9.51K | ﹤0.01% | 6338 |
|
|
2025
Q1 | $6K | Sell |
514
-574
| -53% | -$9.97K | ﹤0.01% | 6308 |
|
|
2024
Q4 | $25K | Sell |
1,088
-403
| -27% | -$15K | ﹤0.01% | 6025 |
|
|
2024
Q3 | $63K | Buy |
1,491
+492
| +49% | +$19.1K | ﹤0.01% | 5592 |
|
|
2024
Q2 | $36K | Buy |
+999
| New | +$35.2K | ﹤0.01% | 5804 |
|
|
2024
Q1 | – | Sell |
-104
| Closed | -$2K | – | 7395 |
|
|
2023
Q4 | $2K | Buy |
+104
| New | +$1.49K | ﹤0.01% | 6824 |
|
|
2023
Q3 | – | Sell |
-30
| Closed | – | – | 7399 |
|
|
2023
Q2 | $0 | Buy |
30
+20
| +200% | +$328 | ﹤0.01% | 7523 |
|
|
2023
Q1 | $0 | Hold |
10
| – | – | ﹤0.01% | 7339 |
|
|
2022
Q4 | $0 | Sell |
10
-16
| -62% | -$165 | ﹤0.01% | 7547 |
|
|
2022
Q3 | $0 | Buy |
26
+15
| +136% | +$306 | ﹤0.01% | 7703 |
|
|
2022
Q2 | $0 | Sell |
11
-172
| -94% | -$4.2K | ﹤0.01% | 7593 |
|
|
2022
Q1 | $7K | Sell |
183
-264
| -59% | -$15.4K | ﹤0.01% | 7114 |
|
|
2021
Q4 | $43K | Buy |
447
+158
| +55% | +$19.2K | ﹤0.01% | 6452 |
|
|
2021
Q3 | $42K | Sell |
289
-82
| -22% | -$12.6K | ﹤0.01% | 6265 |
|
|
2021
Q2 | $68K | Sell |
371
-103
| -22% | -$22.8K | ﹤0.01% | 5832 |
|
|
2021
Q1 | $117K | Buy |
474
+60
| +14% | +$15.3K | ﹤0.01% | 5348 |
|
|
2020
Q4 | $117K | Buy |
414
+112
| +37% | +$27.4K | ﹤0.01% | 5245 |
|
|
2020
Q3 | $72K | Sell |
302
-262
| -46% | -$63.5K | ﹤0.01% | 5158 |
|
|
2020
Q2 | $187K | Sell |
564
-2,870
| -84% | -$748K | ﹤0.01% | 4503 |
|
|
2020
Q1 | $781K | Buy |
3,434
+916
| +36% | +$188K | ﹤0.01% | 3230 |
|
|
2019
Q4 | $621K | Sell |
2,518
-2,541
| -50% | -$253K | ﹤0.01% | 3814 |
|
|
2019
Q3 | $289K | Buy |
5,059
+1,452
| +40% | +$88.6K | ﹤0.01% | 4209 |
|
|
2019
Q2 | $170K | Buy |
+3,607
| New | +$185K | ﹤0.01% | 4567 |
|
|
2019
Q1 | – | Hold |
0
| – | – | – | 6993 |
|
|
2018
Q4 | – | Hold |
0
| – | – | – | 6992 |
|
|
2018
Q3 | – | Hold |
0
| – | – | – | 6870 |
|
|
2015
Q3 | – | Sell |
-750
| Closed | -$104K | – | 6736 |
|
|
2015
Q2 | $104K | Buy |
750
+747
| +24,900% | +$114K | ﹤0.01% | 4803 |
|
|
2015
Q1 | $0 | Buy |
+3
| New | +$610 | ﹤0.01% | 6324 |
|
Other funds holding NGNE
SB
RG
CC
RI
EC
BBA
TECP
Royal Bank of Canada's NGNE Position: Q1 2026 in Review
Royal Bank of Canada reduced its Neurogene (NGNE) stake by 74% in Q1 2026, selling an estimated $6.16K and leaving 112 shares worth $2K. The position accounts for ﹤0.01% of the portfolio, ranked #6729.
Royal Bank of Canada first reported a position in NGNE in Q1 2015 and has held it in 28 quarters since. The position peaked at $781K in Q1 2020. 96 funds tracked by Wall St. Rank hold NGNE as of Q1 2026.
- Royal Bank of Canada held 112 shares of Neurogene worth $2K as of Q1 2026.
- Royal Bank of Canada sold 318 Neurogene shares in Q1 2026, an estimated $6.16K.
- Neurogene made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #6729 holding.
- Royal Bank of Canada first reported a position in Neurogene in Q1 2015 and has held it in 28 quarters since.
- Royal Bank of Canada's Neurogene position peaked at $781K in Q1 2020.
- 96 funds tracked by Wall St. Rank held Neurogene as of Q1 2026.
Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.